Application of oxibenzophenone in preparation of medicine for treating pathological cardiac hypertrophy and / or heart failure

By inhibiting phenylephrine-induced pathological hypertrophy of cardiomyocytes and improving cardiac dysfunction caused by aortic arch stenosis, ethoxybenzone solves the problem of the difficulty in effectively intervening in pathological myocardial hypertrophy in existing technologies, achieves the effect of reducing myocardial hypertrophy and cardiac fibrosis, and has significant clinical application value.

CN120605264APending Publication Date: 2025-09-09SHANGHAI UNIV
0 Cites 2 Cited by

Patent Information

Application Number
CN202510978190.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-07-15
Publication Date
2025-09-09

AI Technical Summary

Technical Problem

Existing drugs are difficult to fundamentally inhibit the pathological process of pathological myocardial hypertrophy. Clinical treatment mainly focuses on improving symptoms, and there is a lack of effective intervention strategies to reduce the incidence of heart failure.

Method used

Exifone is used as the active ingredient to inhibit the pathological hypertrophy of cardiomyocytes induced by phenylephrine (PE), improve cardiac function disorders caused by aortic arch constriction (TAC), and reduce myocardial hypertrophy and cardiac tissue fibrosis.

Benefits of technology

Ethyphenidol can inhibit pathological hypertrophy of cardiomyocytes, improve cardiac dysfunction, reduce myocardial hypertrophy and cardiac fibrosis, providing new drug development pathways and targets, and has important theoretical research and clinical application value.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to application of oxibenzophenone in preparation of a medicine for treating pathological cardiac hypertrophy and / or heart failure. Research results in myocardial cells of primary newborn rats show that Exibenzophenone can inhibit pathological hypertrophy of myocardial cells induced by phenylephrine (PE). Animal experiments show that the epoxybenzophenone can improve cardiac dysfunction induced by aortic arch constriction (TAC) and reduce cardiac hypertrophy and cardiac tissue fibrosis. The invention provides a new drug research and development approach and a drug action target for treating pathological cardiac hypertrophy and heart failure, and has very important medicinal value.
Need to check novelty before this filing date? Find Prior Art